List of Implants Companies in Florida - 14

Amend Surgical leads the biopharmaceutical industry in promoting development of bone healing with NanoFuse, a bone graft substitute and bone void filler.

Cadrenal Therapeutics is a late-stage biopharmaceutical company developing tecarfarin, an oral therapeutic designed to be a superior and safer Vitamin K antagonist (VKA) anticoagulant for patients with implanted cardiac devices or rare cardiovascular (CV) conditions. Cadrenal strives to improve outcomes and reduce adverse events for these patients such as strokes, heart attacks, bleeds, and deaths. These patients also lack approved chronic anticoagulation options besides warfarin, well-known for its serious side effects and frequent drug-drug interactions, resulting in complicated treatment management. Cadrenal’s drug candidate, tecarfarin, is a new VKA anticoagulant with extensive clinical data showing it is potentially superior and safer than warfarin, resulting in fewer adverse events. Tecarfarin is metabolized via a different pathway than warfarin and data demonstrate that its efficacy is unaffected by common drug-drug interactions or kidney impairment, which are common in these patients. Phase 2/3 clinical trials show that tecarfarin may offer more stability and time in therapeutic range (TTR) that inversely correlates with major events. Tecarfarin received an orphan drug designation for advanced heart failure patients with left ventricular assist devices (LVADs) as well as both orphan drug and fast-track status for end-stage kidney disease (ESKD) patients with atrial fibrillation. Cadrenal is opportunistically pursuing pivotal clinical trials with LVAD patients along with clinical and commercial partnership opportunities to advance tecarfarin. The company’s plans also include studying patients with mechanical heart valves who experience anticoagulation difficulties because of genetic warfarin resistance, polypharmacy, or kidney impairment. For more information, please visit: www.cadrenal.com.

Cordis is a medical devices company that specializes in cardiology equipment and healthcare technology.

CTM is dedicated to developing surgical implants to help physicians treat post-operative biologic issues that are beyond their control.

Exactech is a global medical technology company that empowers orthopaedic surgeons with innovative implants, surgical instruments and the Active Intelligence® (AI) ecosystem of smart technologies to give patients EXACTLY what they need to regain mobility. Visit www.exac.com for more information. Exactech will never ask you to conduct an interview via text message. We value your privacy and do not ask applicants for financial information or ask applicants to make any purchases. If you believe that you have been contacted by a cybercriminal, please contact your local police department.

IGENOMIX USA is a biotechnology company that specializes in genetic testing services for reproductive health and fertility.

As a specialized company dedicated to ophthalmology, Santen carries out research, development, marketing, and sales of pharmaceuticals, over-the-counter products, and medical devices. Santen is the market leader for prescription ophthalmic pharmaceuticals in Japan and its products now reach patients in over 60 countries and regions. With scientific knowledge and organizational capabilities nurtured over a 130-year history, Santen provides products and services to contribute to the well-being of patients, their loved ones and consequently to society. Santen Pharmaceutical Official Social Media Global Terms of Use​ https://www.santen.com/en/legal/

iTolerance is a privately held regenerative medicine company enabling tissue, organoid or cell therapy without the need for life-long immunosuppression. Leveraging our proprietary technology platform, iTOL-100, we are advancing a pipeline of programs using both allogenic pancreatic islets and stem-cells that have the potential to cure diseases. Our lead program, iTOL-101 is being developed for Type 1 Diabetes and in a preclinical non-human primate study, pancreatic islet cells co-implanted with iTOL-101 exhibited long-term function with control of blood glucose levels and restoration of insulin secretion without the use of chronic immune suppression. Our follow-on candidate, iTOL-102 is leveraging significant advancements in stem cells, which allows a potentially inexhaustible supply of insulin-producing cells for use in Type 1 Diabetes. Additionally, the Company is developing iTOL-201 for liver failure and iTOL-301 as a potential regenerative protein and cell therapy that leverages stem cell sources to produce proteins or hormones in the body in conditions of high unmet need.

Marizyme, Inc. is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical technologies that improve patient health outcomes.

Neocis, the first dental robotics company, is committed to enhancing dental surgeons’ capabilities and advancing patient care. Or Yomi is bringing the power of surgical robotics to dentistry.

The Next Generation of Branched Aortic Stent Grafts A challenging frontier for aortic endovascular repair, complex aortic aneurysms are those involving the take-offs of major arterial branches or short landing zones. Through its patented technology, Red Vascular Technology meets this challenge with the next generation of non-modular branched endografts. Red Vascular Technology, LLC is currently involved in the development of minimally invasive techniques for the treatment of Aortic aneurysms of both the Abdominal and Thoracic Aorta which involve the major branch origins of these vessels. The current state of the art for the treatment of aneurysmal disease which effects the origins of the major branches is the use of "Fenestrations" including Periscope, or Chimney techniques of the endograft and construction of the device in-situ. All these techniques are Modular in nature which means that there are multiple parts of the endograft which must be deployed separately. This increases the complexity, complications and in general the outcomes of such devices. The Red Vascular Technology design and intellectual property allows the branch or branches to be non-modular and therefore the endograft is deployed in "one piece". This technology allows for less complications which in turn significantly increases patient safety and reduces cost.

RTI Surgical (RTI) is a leading CDMO pushing the boundaries of innovation and tissue engineering to meet patient needs in regenerative medicine. We are expert partners to Original Equipment Manufacturers (OEMs), working with them to identify clinical problems and develop customized solutions that promote healing, accelerate recovery, and help prevent complications. We focus on specialized clinical segments, including breast and plastic surgery, sports medicine and orthopedics, and neuro and spine surgery. Our Mission is to enhance patients' lives by creating the best clinical outcomes through innovative, high-quality medical solutions.

Xēnix Medical is a surgical implant company focused on the development of novel science-based solutions for patients requiring spinal fusion surgery. The company, headquartered in Orlando, Florida, markets its line of spinal implant devices in the United States through a network of independent distributors.